Assessing the impact of intravenous immunoglobulin in the management of streptococcal toxic shock syndrome: A noble but difficult quest

Clinical Infectious Diseases

Volumn 49, Issue 9, 2009, Pages 1377-1379

  Valiquette, Louis ^a   Low, Donald E ^b   McGeer, Allison J ^b  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; PLACEBO;

CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; GROUP A STREPTOCOCCAL INFECTION; HOSPITAL COST; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MORTALITY; NECROTIZING FASCIITIS; NOTE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; TOXIC SHOCK SYNDROME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFANT; MALE; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 72849137778     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/606049     Document Type: Note

References (22)

1. Vlaminckx BJ, Van Pelt W, Schouls LM, et al. Long-term surveillance of invasive group A streptococcal disease in The Netherlands, 1994-2003. Clin Microbiol Infect 2005; 11: 226-231
2. OLoughlin RE, Roberson A, Cieslak PR, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis 2007; 45:853-862
3. Laupland KB, Ross T, Church DL, Gregson DB. Population-based surveillance of invasive pyogenic streptococcal infection in a large Canadian region. Clin Microbiol Infect 2006; 12: 224-230 (Pubitemid 43379322) (Pubitemid 43379322)
4. Darenberg J, Ihendyane N, Sjolin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebocontrolled trial. Clin Infect Dis 2003; 37: 333-340 (Pubitemid 36976489) (Pubitemid 36976489)
5. Kaul R, McGeer A, Norrby-Teglund A, et al; The Canadian Streptococcal Study Group. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 1999; 28: 800-807
6. Shah SS, Hall M, Srivastava R, Subramony A, Levin JE. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin Infect Dis 2009; 49:1369-1376 (in this issue).
7. Burnett AM, Domachowske JB. Therapeutic considerations for children with invasive group a streptococcal infections: a case series report and review of the literature. Clin Pediatr (Phila) 2007; 46:550-555
8. Watkins R, Vyas H. Toxic shock syndrome and streptococcal myositis: three case reports. Eur J Pediatr 2002; 161:497-498 (Pubitemid 35013671) (Pubitemid 35013671)
9. Cawley MJ, Briggs M, Haith LR Jr, et al. Intravenous immunoglobulin as adjunctive treatment for streptococcal toxic shock syndrome associated with necrotizing fasciitis: case report and review. Pharmacotherapy 1999; 19:1094-1098 (Pubitemid 29413649) (Pubitemid 29413649)
10. Chiu CH, Ou JT, Chang KS, Lin TY. Successful treatment of severe streptococcal toxic shock syndrome with a combination of intravenous immunoglobulin, dexamethasone and antibiotics. Infection 1997; 25:47-48 (Pubitemid 27075661) (Pubitemid 27075661)
11. Nadal D, Lauener RP, Braegger CP, et al. T cell activation and cytokine release in streptococcal toxic shock-like syndrome. J Pediatr 1993; 122:727-729 (Pubitemid 23134959)
12. Jackson MA, Colombo J, Boldrey A. Streptococcal fasciitis with toxic shock syndrome in the pediatric patient. Orthop Nurs 2003; 22:4-8.
13. Committee on Infectious Diseases, American Academy of Pediatrics. Toxic shock syndrome. In: The red book. 27th ed. Elk Grove Village, IL: Committee on Infectious Diseases, American Academy of Pediatrics, 2006:660-664
14. Valiquette L, Low DE, Chow R, McGeer AJ. A survey of physicians attitudes regarding management of severe group A streptococcal infections. Scand J Infect Dis 2006; 38:977-982 (Pubitemid 44869267) (Pubitemid 44869267)
15. Norrby-Teglund A, Muller MP, McGeer A, et al. Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 2005; 37:166-172 (Pubitemid 40372838) (Pubitemid 40372838)
16. Beaulieu A, et al. Intravenous immunoglobulins for group A streptococcal toxic shock syndrome [abstract k-1365]. In: Program and abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Diseases Society of America 46th Annual Meeting (Washington, DC). 2008.
17. Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman JK, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 2006; 59:437-447
18. Peduzzi P, Concato J, Kemper E, Holdford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49:1373-1379 (Pubitemid 27028925)
19. Austin PC. A critical appraisal of propensity- score matching in the medical literature between 1996 and 2003. Stat Med 2008; 27: 2037-2049
20. Stukel TA, Fisher ES,Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA 2007; 297:278-285
21. Marcin JP, Pollack MM, Patel KM, Ruttimann UE. Decision support issues using a physiology based score. Intensive CareMed 1998; 24: 1299-1304
22. Graciano AL, Balko JA, Rahn DS, Ahmad N, Giroir BP. The Pediatric Multiple Organ Dysfunction Score (P-MODS): development and validation of an objective scale to measure the severity of multiple organ dysfunction in critically ill children. Crit Care Med 2005; 33: 1484-1491 (Pubitemid 40980602) (Pubitemid 40980602)